ClinicalTrials.gg
CompletedNCT00694304Updated Apr 1, 2014Results posted

Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

A Phase 3 interventional study of Vortioxetine (Lu AA21004) in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-04-01.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
535
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
18th of 54
535 · median 413
Started
2008
with 5 others
Phase 3
31 of 54
1 open now
Registered
5th of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 18th largest by enrollment, is one of 6 that started in 2008, is one of 31 in phase 3, and was the 5th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 8-week acute treatment.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • Long-term
  • Safety
  • Open-label
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who completed 8-week short-term treatment study for Major Depressive Episode, NCT00635219 / 11984A

Exclusion criteria

Exclusion Criteria:

  • Any current psychiatric disorder other than MDD as defined in the , Fourth Ed., Text revision (DSM-IV TR)
  • Female patients of who are not using effective
  • Use of any psychoactive medication

Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
535 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    Drug: Vortioxetine (Lu AA21004)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Patients With Adverse Events (AEs)

    Time frame: Baseline to end of the 4-week safety follow-up period

  2. Percentage of Patients Who Withdrew Due to Intolerance to Treatment

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Change From Baseline in MADRS Total Score After 52 Weeks of Treatment

    The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.

    Time frame: Baseline and Week 52

  2. Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment

    The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.

    Time frame: Baseline and Week 52

  3. Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment

    The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.

    Time frame: Baseline and Week 52

  4. Change From Baseline in CGI-S Score After 52 Weeks of Treatment

    The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.

    Time frame: Baseline and Week 52

  5. Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)

    Time frame: Week 52

  6. Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)

    Time frame: Week 52

  7. Proportion of Patients With a MADRS Total Score >=22 After 52 Weeks of Treatment

    Time frame: Baseline and Week 52

  8. Change From Baseline in SDS Total Score After 52 Weeks of Treatment

    The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.

    Time frame: Baseline and Week 52

07

Results

Posted Apr 1, 2014

Participant flow

Patients eligible to participate in Study 11984B were patients who had completed lead-in Study NCT00635219 / 11984A immediately prior to inclusion into Study 11984B.

Participant flow — Overall Study
MilestoneVortioxetine 2.5, 5, or 10 mg/Day
Started535
Completed328
Not completed207
Withdrew: Adverse event42
Withdrew: Lack of efficacy35
Withdrew: Non-compliance with study product16
Withdrew: Protocol violation6
Withdrew: Withdrawal of consent61
Withdrew: Lost to follow-up15
Withdrew: Administrative or other reasons32

Outcome measures

PrimaryNumber of Patients With Adverse Events (AEs)
Time frame:
Baseline to end of the 4-week safety follow-up period
Reported as:
Number · participants
Number of Patients With Adverse Events (AEs)
participantsVortioxetine 2.5, 5, or 10 mg/Day
Patients With AEs391
Patients With SAEs18
Patients With AEs Leading to Withdrawal42
PrimaryPercentage of Patients Who Withdrew Due to Intolerance to Treatment
Time frame:
Baseline to Week 52
Reported as:
Number · percentage of patients
Percentage of Patients Who Withdrew Due to Intolerance to Treatment
percentage of patientsVortioxetine 2.5, 5, or 10 mg/Day
Percentage of Patients Who Withdrew Due to Intolerance to Treatment7.7
SecondaryChange From Baseline in MADRS Total Score After 52 Weeks of Treatment

The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 (no symptom) to 6 (severe symptom). The 10 items represent the core symptoms of depressive illness. The rating should be based on a clinical interview with the patient, moving from broadly phrased questions about symptoms to more detailed ones, which allow a precise rating of severity, covering the last 7 days. Total score from 0 to 60. The higher the score, the more severe.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in MADRS Total Score After 52 Weeks of Treatment
units on a scaleVortioxetine 2.5, 5, or 10 mg/Day
Change From Baseline in MADRS Total Score After 52 Weeks of Treatment-7.35 ± 8.21
SecondaryChange From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment

The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment
units on a scaleVortioxetine 2.5, 5, or 10 mg/Day
Change From Baseline in HAM-D-24 Total Score After 52 Weeks of Treatment-6.86 ± 8.45
SecondaryChange From Baseline in HAM-A Total Score After 52 Weeks of Treatment

The Hamilton Anxiety Rating Scale (HAM-A) consists of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behaviour at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic, and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total score from 0 to 56. The higher the score, the more severe.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment
units on a scaleVortioxetine 2.5, 5, or 10 mg/Day
Change From Baseline in HAM-A Total Score After 52 Weeks of Treatment-5.44 ± 7.08
SecondaryChange From Baseline in CGI-S Score After 52 Weeks of Treatment

The Clinical Global Impression - Severity of Illness (CGI-S) is a 7-point scale rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The investigator should use his/her total clinical experience with this patient population to judge how mentally ill the patient is at the time of rating.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in CGI-S Score After 52 Weeks of Treatment
units on a scaleVortioxetine 2.5, 5, or 10 mg/Day
Change From Baseline in CGI-S Score After 52 Weeks of Treatment-1.00 ± 1.22
SecondaryProportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)
Time frame:
Week 52
Reported as:
Mean · percentage of patients
Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)
percentage of patientsVortioxetine 2.5, 5, or 10 mg/Day
Proportion of Responders at Week 52 (Response Defined as a >=50% Decrease in MADRS Total Score)94.2 ± 23.4
SecondaryProportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)
Time frame:
Week 52
Reported as:
Mean · percentage of patients
Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)
percentage of patientsVortioxetine 2.5, 5, or 10 mg/Day
Proportion of Remitters at Week 52 (Remission Defined as a MADRS Total Score <=10)83.0 ± 37.6
SecondaryProportion of Patients With a MADRS Total Score >=22 After 52 Weeks of Treatment
Time frame:
Baseline and Week 52
Reported as:
Number · percentage of patients
Proportion of Patients With a MADRS Total Score >=22 After 52 Weeks of Treatment
percentage of patientsVortioxetine 2.5, 5, or 10 mg/Day
Proportion of Patients With a MADRS Total Score >=22 After 52 Weeks of Treatment2.74
SecondaryChange From Baseline in SDS Total Score After 52 Weeks of Treatment

The Sheehan Disability Scale (SDS) comprises self-rated items designed to measure impairment. The patient rates the extent to which his or her (1) work, (2) social life or leisure activities and (3) home life or family responsibilities are impaired on a 10-point visual analogue scales, on which 0 = normal functioning and 10 = severe functional impairment. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). The higher the score, the more severe.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in SDS Total Score After 52 Weeks of Treatment
units on a scaleVortioxetine 2.5, 5, or 10 mg/Day
Change From Baseline in SDS Total Score After 52 Weeks of Treatment-5.60 ± 6.91

Adverse events

Collected over Serious Adverse Events: 52-week open label period and 4-week safety follow-up period Other Adverse Events: 52-week open label period. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine 2.5, 5, or 10 mg/Day—18/535 (3.4%)256/535 (47.9%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventVortioxetine 2.5, 5, or 10 mg/Day
DepressionPsychiatric disorders3/535
Suicidal ideationPsychiatric disorders3/535
MenorrhagiaReproductive system and breast disorders1/366
Chest painGeneral disorders1/535
AppendicitisInfections and infestations1/535
PneumoniaInfections and infestations1/535
Intentional overdoseInjury, poisoning and procedural complications1/535
Road traffic accidentInjury, poisoning and procedural complications1/535
Back painMusculoskeletal and connective tissue disorders1/535
Muscle spasmsMusculoskeletal and connective tissue disorders1/535
Most frequent other events
Most frequent other events
EventVortioxetine 2.5, 5, or 10 mg/Day
NauseaGastrointestinal disorders106/535
HeadacheNervous system disorders82/535
NasopharyngitisInfections and infestations56/535
InsomniaPsychiatric disorders38/535
DizzinessNervous system disorders34/535
Weight increasedInvestigations31/535
Accidental overdoseInjury, poisoning and procedural complications29/535
InfluenzaInfections and infestations27/535

Baseline characteristics

Age and Sex: all-patients-treated set (APTS) - all patients who took at least one dose of Vortioxetine after Baseline; MADRS, HAM-D-24, HAM-A, CGI-S and SDS: full-analysis set (FAS) - all patients in the APTS who had at least one valid post-Baseline assessment of the MADRS total score.

Age, Continuous
Age, Continuous(years)Vortioxetine 2.5, 5, or 10 mg/Day
Mean45.7 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Vortioxetine 2.5, 5, or 10 mg/Day
Female366
Male169
MADRS
MADRS(units on a scale)Vortioxetine 2.5, 5, or 10 mg/Day
Mean13.5 ± 8.7
HAM-D-24
HAM-D-24(units on a scale)Vortioxetine 2.5, 5, or 10 mg/Day
Mean13.4 ± 8.7
HAM-A
HAM-A(units on a scale)Vortioxetine 2.5, 5, or 10 mg/Day
Mean11.0 ± 7.2
CGI-S
CGI-S(units on a scale)Vortioxetine 2.5, 5, or 10 mg/Day
Mean2.7 ± 1.2
SDS
SDS(units on a scale)Vortioxetine 2.5, 5, or 10 mg/Day
Mean12.42 ± 8.13
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012 Oct;28(10):1717-24. doi: 10.1185/03007995.2012.725035. Epub 2012 Sep 17. PubMed 22978748 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Mar 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2008
First posted
Jun 10, 2008
Start
May 2008
Primary completionActual
Mar 2010
CompletionActual
Apr 2010
Results first posted
Apr 1, 2014
Last update
Apr 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00694304
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jun 10, 2008
Start date
May 2008
Primary completion
Mar 2010
Completion
Apr 2010
Results posted
Apr 1, 2014
Last update
Apr 1, 2014

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion